Clinical Trial: Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07408427) titled 'Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy' on Feb. 06.

Brief Summary: This research study, aims to understand why a specific heart medication called mavacamten works better for some people with hypertrophic cardiomyopathy (HCM) than for others. We believe the answer might be in our genes.

The study focuses on two key areas:

1. The specific gene causing HCM:The study will investigate whether the type of gene causing the condition in a person influences how well mavacamten works for them.

2. Each individual carry a certain gene that helps metabol...